Comment: PARP inhibitors for advanced prostate cancer

PARP inhibitor olaparib slows progression of advanced prostate cancer

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy

Providing quality patient care and service using the Oncology Care Model

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer

Breast cancer highlights from ASCO 2019

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

Better education about breast cancer treatment in Africa